nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Carboplatin—esophageal cancer	0.227	0.514	CbGbCtD
Bortezomib—PTGS1—esophageal cancer	0.212	1	CbGaD
Bortezomib—SLC31A1—Cisplatin—esophageal cancer	0.194	0.44	CbGbCtD
Bortezomib—CYP2C9—Capecitabine—esophageal cancer	0.0136	0.0308	CbGbCtD
Bortezomib—CYP2C9—Cisplatin—esophageal cancer	0.00685	0.0155	CbGbCtD
Bortezomib—PSMA1—epithelium—esophageal cancer	0.00225	0.0392	CbGeAlD
Bortezomib—CTSG—trachea—esophageal cancer	0.00207	0.0361	CbGeAlD
Bortezomib—PSMD1—bronchus—esophageal cancer	0.00186	0.0324	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—esophageal cancer	0.00182	0.0317	CbGeAlD
Bortezomib—PSMA1—digestive system—esophageal cancer	0.00171	0.0298	CbGeAlD
Bortezomib—PSMD1—trachea—esophageal cancer	0.00167	0.0291	CbGeAlD
Bortezomib—PSMD2—bronchus—esophageal cancer	0.00165	0.0287	CbGeAlD
Bortezomib—PSMB8—bronchus—esophageal cancer	0.00164	0.0285	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—esophageal cancer	0.00161	0.0281	CbGeAlD
Bortezomib—CTSG—lung—esophageal cancer	0.00149	0.0259	CbGeAlD
Bortezomib—PSMD2—trachea—esophageal cancer	0.00148	0.0258	CbGeAlD
Bortezomib—PSMB8—trachea—esophageal cancer	0.00147	0.0256	CbGeAlD
Bortezomib—PSMB5—bronchus—esophageal cancer	0.00144	0.0252	CbGeAlD
Bortezomib—PSMA1—lung—esophageal cancer	0.00143	0.0249	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—esophageal cancer	0.00141	0.0247	CbGeAlD
Bortezomib—PSMB5—trachea—esophageal cancer	0.0013	0.0226	CbGeAlD
Bortezomib—PSMD2—digestive system—esophageal cancer	0.00127	0.0222	CbGeAlD
Bortezomib—PSMB1—bronchus—esophageal cancer	0.00126	0.022	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—esophageal cancer	0.00124	0.0216	CbGeAlD
Bortezomib—PSMB2—bronchus—esophageal cancer	0.00123	0.0215	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—esophageal cancer	0.00121	0.021	CbGeAlD
Bortezomib—PSMD1—lung—esophageal cancer	0.0012	0.0209	CbGeAlD
Bortezomib—PSMB1—trachea—esophageal cancer	0.00113	0.0198	CbGeAlD
Bortezomib—PSMB2—trachea—esophageal cancer	0.00111	0.0193	CbGeAlD
Bortezomib—SLC31A1—bronchus—esophageal cancer	0.00107	0.0186	CbGeAlD
Bortezomib—PSMD2—lung—esophageal cancer	0.00106	0.0185	CbGeAlD
Bortezomib—PSMB8—lung—esophageal cancer	0.00105	0.0184	CbGeAlD
Bortezomib—CTSG—lymph node—esophageal cancer	0.00102	0.0177	CbGeAlD
Bortezomib—Lacosamide—CA1—esophageal cancer	0.000983	0.474	CrCbGaD
Bortezomib—PSMA1—lymph node—esophageal cancer	0.000976	0.017	CbGeAlD
Bortezomib—PSMB1—digestive system—esophageal cancer	0.000975	0.017	CbGeAlD
Bortezomib—SLC31A1—trachea—esophageal cancer	0.000958	0.0167	CbGeAlD
Bortezomib—PSMB2—digestive system—esophageal cancer	0.000952	0.0166	CbGeAlD
Bortezomib—PSMB5—lung—esophageal cancer	0.000932	0.0163	CbGeAlD
Bortezomib—SLC31A1—digestive system—esophageal cancer	0.000824	0.0144	CbGeAlD
Bortezomib—PSMD1—lymph node—esophageal cancer	0.00082	0.0143	CbGeAlD
Bortezomib—PSMB1—lung—esophageal cancer	0.000814	0.0142	CbGeAlD
Bortezomib—PSMB2—lung—esophageal cancer	0.000795	0.0139	CbGeAlD
Bortezomib—Lacosamide—CA2—esophageal cancer	0.000745	0.359	CrCbGaD
Bortezomib—PSMD2—lymph node—esophageal cancer	0.000726	0.0127	CbGeAlD
Bortezomib—PSMB8—lymph node—esophageal cancer	0.000721	0.0126	CbGeAlD
Bortezomib—SLC31A1—lung—esophageal cancer	0.000688	0.012	CbGeAlD
Bortezomib—PSMB5—lymph node—esophageal cancer	0.000637	0.0111	CbGeAlD
Bortezomib—PSMB1—lymph node—esophageal cancer	0.000557	0.00972	CbGeAlD
Bortezomib—PSMB2—lymph node—esophageal cancer	0.000544	0.00949	CbGeAlD
Bortezomib—SLC31A1—lymph node—esophageal cancer	0.000471	0.00822	CbGeAlD
Bortezomib—CYP1A1—epithelium—esophageal cancer	0.000368	0.00642	CbGeAlD
Bortezomib—CYP1A1—bronchus—esophageal cancer	0.000362	0.00632	CbGeAlD
Bortezomib—CYP2C19—digestive system—esophageal cancer	0.000347	0.00606	CbGeAlD
Bortezomib—Nateglinide—PTGS1—esophageal cancer	0.000345	0.166	CrCbGaD
Bortezomib—CYP1A1—trachea—esophageal cancer	0.000325	0.00568	CbGeAlD
Bortezomib—PTGS1—epithelium—esophageal cancer	0.000323	0.00564	CbGeAlD
Bortezomib—PTGS1—smooth muscle tissue—esophageal cancer	0.000311	0.00544	CbGeAlD
Bortezomib—PTGS1—trachea—esophageal cancer	0.000286	0.00499	CbGeAlD
Bortezomib—CYP1A2—digestive system—esophageal cancer	0.000284	0.00495	CbGeAlD
Bortezomib—CYP1A1—digestive system—esophageal cancer	0.00028	0.00489	CbGeAlD
Bortezomib—CYP2C9—digestive system—esophageal cancer	0.000269	0.0047	CbGeAlD
Bortezomib—PTGS1—digestive system—esophageal cancer	0.000246	0.00429	CbGeAlD
Bortezomib—CYP1A2—lung—esophageal cancer	0.000237	0.00414	CbGeAlD
Bortezomib—CYP1A1—lung—esophageal cancer	0.000234	0.00408	CbGeAlD
Bortezomib—CYP3A4—digestive system—esophageal cancer	0.000205	0.00359	CbGeAlD
Bortezomib—PTGS1—lung—esophageal cancer	0.000205	0.00358	CbGeAlD
Bortezomib—CYP2D6—digestive system—esophageal cancer	0.000202	0.00353	CbGeAlD
Bortezomib—CYP1A1—lymph node—esophageal cancer	0.00016	0.00279	CbGeAlD
Bortezomib—PTGS1—lymph node—esophageal cancer	0.00014	0.00245	CbGeAlD
Bortezomib—Muscular weakness—Capecitabine—esophageal cancer	0.000115	0.00105	CcSEcCtD
Bortezomib—Eye disorder—Cisplatin—esophageal cancer	0.000115	0.00105	CcSEcCtD
Bortezomib—Tinnitus—Cisplatin—esophageal cancer	0.000114	0.00104	CcSEcCtD
Bortezomib—Lymphadenopathy—Methotrexate—esophageal cancer	0.000114	0.00104	CcSEcCtD
Bortezomib—Flushing—Cisplatin—esophageal cancer	0.000114	0.00104	CcSEcCtD
Bortezomib—Cardiac disorder—Cisplatin—esophageal cancer	0.000114	0.00104	CcSEcCtD
Bortezomib—Abdominal distension—Capecitabine—esophageal cancer	0.000114	0.00104	CcSEcCtD
Bortezomib—Dysphagia—Capecitabine—esophageal cancer	0.000113	0.00103	CcSEcCtD
Bortezomib—Influenza—Capecitabine—esophageal cancer	0.000113	0.00103	CcSEcCtD
Bortezomib—Thrombophlebitis—Methotrexate—esophageal cancer	0.000113	0.00103	CcSEcCtD
Bortezomib—Diabetes mellitus—Methotrexate—esophageal cancer	0.000112	0.00102	CcSEcCtD
Bortezomib—Bronchospasm—Capecitabine—esophageal cancer	0.000111	0.00101	CcSEcCtD
Bortezomib—Immune system disorder—Cisplatin—esophageal cancer	0.000111	0.00101	CcSEcCtD
Bortezomib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000111	0.00101	CcSEcCtD
Bortezomib—Angina pectoris—Capecitabine—esophageal cancer	0.00011	0.001	CcSEcCtD
Bortezomib—Arrhythmia—Cisplatin—esophageal cancer	0.00011	0.000999	CcSEcCtD
Bortezomib—Bronchitis—Capecitabine—esophageal cancer	0.000109	0.000991	CcSEcCtD
Bortezomib—Abdominal discomfort—Capecitabine—esophageal cancer	0.000108	0.000988	CcSEcCtD
Bortezomib—Hepatic failure—Methotrexate—esophageal cancer	0.000108	0.000987	CcSEcCtD
Bortezomib—Pancytopenia—Capecitabine—esophageal cancer	0.000107	0.000978	CcSEcCtD
Bortezomib—Malnutrition—Cisplatin—esophageal cancer	0.000107	0.000974	CcSEcCtD
Bortezomib—Erythema—Cisplatin—esophageal cancer	0.000107	0.000974	CcSEcCtD
Bortezomib—Neutropenia—Capecitabine—esophageal cancer	0.000106	0.000963	CcSEcCtD
Bortezomib—Renal failure acute—Methotrexate—esophageal cancer	0.000105	0.000961	CcSEcCtD
Bortezomib—Flatulence—Cisplatin—esophageal cancer	0.000105	0.00096	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000105	0.000957	CcSEcCtD
Bortezomib—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000103	0.00094	CcSEcCtD
Bortezomib—Weight increased—Capecitabine—esophageal cancer	0.000103	0.000938	CcSEcCtD
Bortezomib—Muscle spasms—Cisplatin—esophageal cancer	0.000103	0.000936	CcSEcCtD
Bortezomib—Weight decreased—Capecitabine—esophageal cancer	0.000102	0.000932	CcSEcCtD
Bortezomib—Hyperglycaemia—Capecitabine—esophageal cancer	0.000102	0.000929	CcSEcCtD
Bortezomib—Pneumonia—Capecitabine—esophageal cancer	0.000101	0.000924	CcSEcCtD
Bortezomib—Infestation NOS—Capecitabine—esophageal cancer	0.000101	0.000919	CcSEcCtD
Bortezomib—Infestation—Capecitabine—esophageal cancer	0.000101	0.000919	CcSEcCtD
Bortezomib—Vision blurred—Cisplatin—esophageal cancer	0.000101	0.000918	CcSEcCtD
Bortezomib—Tremor—Cisplatin—esophageal cancer	0.0001	0.000912	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.0001	0.000911	CcSEcCtD
Bortezomib—Acute coronary syndrome—Capecitabine—esophageal cancer	9.94e-05	0.000906	CcSEcCtD
Bortezomib—Lethargy—Methotrexate—esophageal cancer	9.94e-05	0.000906	CcSEcCtD
Bortezomib—Ill-defined disorder—Cisplatin—esophageal cancer	9.92e-05	0.000904	CcSEcCtD
Bortezomib—Renal failure—Capecitabine—esophageal cancer	9.91e-05	0.000903	CcSEcCtD
Bortezomib—Myocardial infarction—Capecitabine—esophageal cancer	9.88e-05	0.0009	CcSEcCtD
Bortezomib—Neuropathy peripheral—Capecitabine—esophageal cancer	9.88e-05	0.0009	CcSEcCtD
Bortezomib—Anaemia—Cisplatin—esophageal cancer	9.88e-05	0.0009	CcSEcCtD
Bortezomib—Stomatitis—Capecitabine—esophageal cancer	9.83e-05	0.000895	CcSEcCtD
Bortezomib—Conjunctivitis—Capecitabine—esophageal cancer	9.8e-05	0.000893	CcSEcCtD
Bortezomib—Urinary tract infection—Capecitabine—esophageal cancer	9.8e-05	0.000893	CcSEcCtD
Bortezomib—Osteoarthritis—Methotrexate—esophageal cancer	9.74e-05	0.000887	CcSEcCtD
Bortezomib—Malaise—Cisplatin—esophageal cancer	9.64e-05	0.000878	CcSEcCtD
Bortezomib—Haematuria—Capecitabine—esophageal cancer	9.61e-05	0.000876	CcSEcCtD
Bortezomib—Leukopenia—Cisplatin—esophageal cancer	9.57e-05	0.000872	CcSEcCtD
Bortezomib—Hepatobiliary disease—Capecitabine—esophageal cancer	9.54e-05	0.000869	CcSEcCtD
Bortezomib—Epistaxis—Capecitabine—esophageal cancer	9.51e-05	0.000866	CcSEcCtD
Bortezomib—Irritability—Methotrexate—esophageal cancer	9.3e-05	0.000847	CcSEcCtD
Bortezomib—Convulsion—Cisplatin—esophageal cancer	9.26e-05	0.000844	CcSEcCtD
Bortezomib—Bradycardia—Capecitabine—esophageal cancer	9.21e-05	0.000839	CcSEcCtD
Bortezomib—Ataxia—Methotrexate—esophageal cancer	9.16e-05	0.000834	CcSEcCtD
Bortezomib—Myalgia—Cisplatin—esophageal cancer	9.1e-05	0.000829	CcSEcCtD
Bortezomib—Haemoglobin—Capecitabine—esophageal cancer	9.1e-05	0.000829	CcSEcCtD
Bortezomib—Anxiety—Cisplatin—esophageal cancer	9.07e-05	0.000826	CcSEcCtD
Bortezomib—Hepatitis—Capecitabine—esophageal cancer	9.05e-05	0.000825	CcSEcCtD
Bortezomib—Haemorrhage—Capecitabine—esophageal cancer	9.05e-05	0.000825	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	9.04e-05	0.000823	CcSEcCtD
Bortezomib—Hypoaesthesia—Capecitabine—esophageal cancer	9.01e-05	0.00082	CcSEcCtD
Bortezomib—Discomfort—Cisplatin—esophageal cancer	8.99e-05	0.000819	CcSEcCtD
Bortezomib—Urinary tract disorder—Capecitabine—esophageal cancer	8.94e-05	0.000814	CcSEcCtD
Bortezomib—Oedema peripheral—Capecitabine—esophageal cancer	8.92e-05	0.000812	CcSEcCtD
Bortezomib—Connective tissue disorder—Capecitabine—esophageal cancer	8.89e-05	0.00081	CcSEcCtD
Bortezomib—Urethral disorder—Capecitabine—esophageal cancer	8.87e-05	0.000808	CcSEcCtD
Bortezomib—Breast disorder—Methotrexate—esophageal cancer	8.8e-05	0.000802	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	8.77e-05	0.000799	CcSEcCtD
Bortezomib—Anaphylactic shock—Cisplatin—esophageal cancer	8.72e-05	0.000795	CcSEcCtD
Bortezomib—Oedema—Cisplatin—esophageal cancer	8.72e-05	0.000795	CcSEcCtD
Bortezomib—Visual impairment—Capecitabine—esophageal cancer	8.72e-05	0.000795	CcSEcCtD
Bortezomib—Infection—Cisplatin—esophageal cancer	8.67e-05	0.00079	CcSEcCtD
Bortezomib—Erythema multiforme—Capecitabine—esophageal cancer	8.56e-05	0.00078	CcSEcCtD
Bortezomib—Nervous system disorder—Cisplatin—esophageal cancer	8.55e-05	0.000779	CcSEcCtD
Bortezomib—Thrombocytopenia—Cisplatin—esophageal cancer	8.54e-05	0.000778	CcSEcCtD
Bortezomib—Tachycardia—Cisplatin—esophageal cancer	8.51e-05	0.000776	CcSEcCtD
Bortezomib—Skin disorder—Cisplatin—esophageal cancer	8.47e-05	0.000772	CcSEcCtD
Bortezomib—Eye disorder—Capecitabine—esophageal cancer	8.46e-05	0.000771	CcSEcCtD
Bortezomib—Tinnitus—Capecitabine—esophageal cancer	8.44e-05	0.000769	CcSEcCtD
Bortezomib—Hyperhidrosis—Cisplatin—esophageal cancer	8.43e-05	0.000768	CcSEcCtD
Bortezomib—Flushing—Capecitabine—esophageal cancer	8.4e-05	0.000765	CcSEcCtD
Bortezomib—Cardiac disorder—Capecitabine—esophageal cancer	8.4e-05	0.000765	CcSEcCtD
Bortezomib—Anorexia—Cisplatin—esophageal cancer	8.32e-05	0.000758	CcSEcCtD
Bortezomib—Pancreatitis—Methotrexate—esophageal cancer	8.25e-05	0.000752	CcSEcCtD
Bortezomib—Angiopathy—Capecitabine—esophageal cancer	8.21e-05	0.000748	CcSEcCtD
Bortezomib—Immune system disorder—Capecitabine—esophageal cancer	8.18e-05	0.000745	CcSEcCtD
Bortezomib—Mediastinal disorder—Capecitabine—esophageal cancer	8.16e-05	0.000743	CcSEcCtD
Bortezomib—Hypotension—Cisplatin—esophageal cancer	8.15e-05	0.000743	CcSEcCtD
Bortezomib—Chills—Capecitabine—esophageal cancer	8.12e-05	0.00074	CcSEcCtD
Bortezomib—Arrhythmia—Capecitabine—esophageal cancer	8.09e-05	0.000737	CcSEcCtD
Bortezomib—Abdominal discomfort—Methotrexate—esophageal cancer	8.07e-05	0.000735	CcSEcCtD
Bortezomib—Pancytopenia—Methotrexate—esophageal cancer	7.99e-05	0.000728	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	7.95e-05	0.000724	CcSEcCtD
Bortezomib—Mental disorder—Capecitabine—esophageal cancer	7.93e-05	0.000722	CcSEcCtD
Bortezomib—Erythema—Capecitabine—esophageal cancer	7.88e-05	0.000718	CcSEcCtD
Bortezomib—Malnutrition—Capecitabine—esophageal cancer	7.88e-05	0.000718	CcSEcCtD
Bortezomib—Neutropenia—Methotrexate—esophageal cancer	7.87e-05	0.000717	CcSEcCtD
Bortezomib—Paraesthesia—Cisplatin—esophageal cancer	7.83e-05	0.000714	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Methotrexate—esophageal cancer	7.82e-05	0.000713	CcSEcCtD
Bortezomib—Dyspnoea—Cisplatin—esophageal cancer	7.78e-05	0.000709	CcSEcCtD
Bortezomib—Flatulence—Capecitabine—esophageal cancer	7.76e-05	0.000707	CcSEcCtD
Bortezomib—Erectile dysfunction—Methotrexate—esophageal cancer	7.75e-05	0.000706	CcSEcCtD
Bortezomib—Dysgeusia—Capecitabine—esophageal cancer	7.72e-05	0.000703	CcSEcCtD
Bortezomib—Photosensitivity reaction—Methotrexate—esophageal cancer	7.68e-05	0.0007	CcSEcCtD
Bortezomib—Back pain—Capecitabine—esophageal cancer	7.62e-05	0.000694	CcSEcCtD
Bortezomib—Decreased appetite—Cisplatin—esophageal cancer	7.58e-05	0.000691	CcSEcCtD
Bortezomib—Muscle spasms—Capecitabine—esophageal cancer	7.58e-05	0.00069	CcSEcCtD
Bortezomib—Pneumonia—Methotrexate—esophageal cancer	7.55e-05	0.000688	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Cisplatin—esophageal cancer	7.53e-05	0.000686	CcSEcCtD
Bortezomib—Infestation NOS—Methotrexate—esophageal cancer	7.51e-05	0.000684	CcSEcCtD
Bortezomib—Infestation—Methotrexate—esophageal cancer	7.51e-05	0.000684	CcSEcCtD
Bortezomib—Pain—Cisplatin—esophageal cancer	7.46e-05	0.00068	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	7.44e-05	0.000678	CcSEcCtD
Bortezomib—Vision blurred—Capecitabine—esophageal cancer	7.43e-05	0.000677	CcSEcCtD
Bortezomib—Tremor—Capecitabine—esophageal cancer	7.38e-05	0.000673	CcSEcCtD
Bortezomib—Renal failure—Methotrexate—esophageal cancer	7.38e-05	0.000672	CcSEcCtD
Bortezomib—Stomatitis—Methotrexate—esophageal cancer	7.32e-05	0.000667	CcSEcCtD
Bortezomib—Ill-defined disorder—Capecitabine—esophageal cancer	7.31e-05	0.000666	CcSEcCtD
Bortezomib—Conjunctivitis—Methotrexate—esophageal cancer	7.3e-05	0.000665	CcSEcCtD
Bortezomib—Anaemia—Capecitabine—esophageal cancer	7.28e-05	0.000663	CcSEcCtD
Bortezomib—Feeling abnormal—Cisplatin—esophageal cancer	7.19e-05	0.000655	CcSEcCtD
Bortezomib—Haematuria—Methotrexate—esophageal cancer	7.16e-05	0.000652	CcSEcCtD
Bortezomib—Malaise—Capecitabine—esophageal cancer	7.11e-05	0.000647	CcSEcCtD
Bortezomib—Hepatobiliary disease—Methotrexate—esophageal cancer	7.1e-05	0.000647	CcSEcCtD
Bortezomib—Epistaxis—Methotrexate—esophageal cancer	7.08e-05	0.000645	CcSEcCtD
Bortezomib—Vertigo—Capecitabine—esophageal cancer	7.08e-05	0.000645	CcSEcCtD
Bortezomib—Syncope—Capecitabine—esophageal cancer	7.07e-05	0.000644	CcSEcCtD
Bortezomib—Leukopenia—Capecitabine—esophageal cancer	7.05e-05	0.000643	CcSEcCtD
Bortezomib—Palpitations—Capecitabine—esophageal cancer	6.96e-05	0.000634	CcSEcCtD
Bortezomib—Loss of consciousness—Capecitabine—esophageal cancer	6.92e-05	0.000631	CcSEcCtD
Bortezomib—Body temperature increased—Cisplatin—esophageal cancer	6.9e-05	0.000628	CcSEcCtD
Bortezomib—Cough—Capecitabine—esophageal cancer	6.88e-05	0.000626	CcSEcCtD
Bortezomib—Hypertension—Capecitabine—esophageal cancer	6.8e-05	0.00062	CcSEcCtD
Bortezomib—Haemoglobin—Methotrexate—esophageal cancer	6.77e-05	0.000617	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—esophageal cancer	6.74e-05	0.000614	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—esophageal cancer	6.74e-05	0.000614	CcSEcCtD
Bortezomib—Arthralgia—Capecitabine—esophageal cancer	6.71e-05	0.000611	CcSEcCtD
Bortezomib—Chest pain—Capecitabine—esophageal cancer	6.71e-05	0.000611	CcSEcCtD
Bortezomib—Myalgia—Capecitabine—esophageal cancer	6.71e-05	0.000611	CcSEcCtD
Bortezomib—Anxiety—Capecitabine—esophageal cancer	6.68e-05	0.000609	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	6.66e-05	0.000607	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—esophageal cancer	6.65e-05	0.000606	CcSEcCtD
Bortezomib—Discomfort—Capecitabine—esophageal cancer	6.63e-05	0.000604	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—esophageal cancer	6.6e-05	0.000602	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—esophageal cancer	6.49e-05	0.000592	CcSEcCtD
Bortezomib—Confusional state—Capecitabine—esophageal cancer	6.48e-05	0.000591	CcSEcCtD
Bortezomib—Oedema—Capecitabine—esophageal cancer	6.43e-05	0.000586	CcSEcCtD
Bortezomib—Hypersensitivity—Cisplatin—esophageal cancer	6.43e-05	0.000586	CcSEcCtD
Bortezomib—Infection—Capecitabine—esophageal cancer	6.39e-05	0.000582	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—esophageal cancer	6.37e-05	0.00058	CcSEcCtD
Bortezomib—Shock—Capecitabine—esophageal cancer	6.33e-05	0.000576	CcSEcCtD
Bortezomib—Nervous system disorder—Capecitabine—esophageal cancer	6.31e-05	0.000575	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—esophageal cancer	6.3e-05	0.000574	CcSEcCtD
Bortezomib—Thrombocytopenia—Capecitabine—esophageal cancer	6.3e-05	0.000574	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—esophageal cancer	6.28e-05	0.000572	CcSEcCtD
Bortezomib—Tachycardia—Capecitabine—esophageal cancer	6.28e-05	0.000572	CcSEcCtD
Bortezomib—Asthenia—Cisplatin—esophageal cancer	6.26e-05	0.00057	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—esophageal cancer	6.25e-05	0.00057	CcSEcCtD
Bortezomib—Skin disorder—Capecitabine—esophageal cancer	6.25e-05	0.000569	CcSEcCtD
Bortezomib—Hyperhidrosis—Capecitabine—esophageal cancer	6.22e-05	0.000566	CcSEcCtD
Bortezomib—Anorexia—Capecitabine—esophageal cancer	6.13e-05	0.000558	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—esophageal cancer	6.11e-05	0.000557	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—esophageal cancer	6.09e-05	0.000554	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—esophageal cancer	6.07e-05	0.000553	CcSEcCtD
Bortezomib—Chills—Methotrexate—esophageal cancer	6.05e-05	0.000551	CcSEcCtD
Bortezomib—Hypotension—Capecitabine—esophageal cancer	6.01e-05	0.000547	CcSEcCtD
Bortezomib—Diarrhoea—Cisplatin—esophageal cancer	5.97e-05	0.000544	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—esophageal cancer	5.9e-05	0.000538	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—esophageal cancer	5.87e-05	0.000534	CcSEcCtD
Bortezomib—Erythema—Methotrexate—esophageal cancer	5.87e-05	0.000534	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	5.86e-05	0.000534	CcSEcCtD
Bortezomib—Insomnia—Capecitabine—esophageal cancer	5.82e-05	0.00053	CcSEcCtD
Bortezomib—Paraesthesia—Capecitabine—esophageal cancer	5.77e-05	0.000526	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—esophageal cancer	5.74e-05	0.000523	CcSEcCtD
Bortezomib—Dyspnoea—Capecitabine—esophageal cancer	5.73e-05	0.000522	CcSEcCtD
Bortezomib—Back pain—Methotrexate—esophageal cancer	5.67e-05	0.000517	CcSEcCtD
Bortezomib—Dyspepsia—Capecitabine—esophageal cancer	5.66e-05	0.000516	CcSEcCtD
Bortezomib—Decreased appetite—Capecitabine—esophageal cancer	5.59e-05	0.000509	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Capecitabine—esophageal cancer	5.55e-05	0.000506	CcSEcCtD
Bortezomib—Vomiting—Cisplatin—esophageal cancer	5.55e-05	0.000505	CcSEcCtD
Bortezomib—Fatigue—Capecitabine—esophageal cancer	5.54e-05	0.000505	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—esophageal cancer	5.53e-05	0.000504	CcSEcCtD
Bortezomib—Rash—Cisplatin—esophageal cancer	5.5e-05	0.000501	CcSEcCtD
Bortezomib—Constipation—Capecitabine—esophageal cancer	5.5e-05	0.000501	CcSEcCtD
Bortezomib—Pain—Capecitabine—esophageal cancer	5.5e-05	0.000501	CcSEcCtD
Bortezomib—Dermatitis—Cisplatin—esophageal cancer	5.5e-05	0.000501	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—esophageal cancer	5.44e-05	0.000496	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—esophageal cancer	5.42e-05	0.000494	CcSEcCtD
Bortezomib—Feeling abnormal—Capecitabine—esophageal cancer	5.3e-05	0.000483	CcSEcCtD
Bortezomib—Malaise—Methotrexate—esophageal cancer	5.29e-05	0.000482	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—esophageal cancer	5.27e-05	0.00048	CcSEcCtD
Bortezomib—Gastrointestinal pain—Capecitabine—esophageal cancer	5.26e-05	0.000479	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—esophageal cancer	5.25e-05	0.000478	CcSEcCtD
Bortezomib—Nausea—Cisplatin—esophageal cancer	5.18e-05	0.000472	CcSEcCtD
Bortezomib—Cough—Methotrexate—esophageal cancer	5.12e-05	0.000466	CcSEcCtD
Bortezomib—Urticaria—Capecitabine—esophageal cancer	5.11e-05	0.000465	CcSEcCtD
Bortezomib—Abdominal pain—Capecitabine—esophageal cancer	5.08e-05	0.000463	CcSEcCtD
Bortezomib—Body temperature increased—Capecitabine—esophageal cancer	5.08e-05	0.000463	CcSEcCtD
Bortezomib—Convulsion—Methotrexate—esophageal cancer	5.08e-05	0.000463	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—esophageal cancer	4.99e-05	0.000455	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—esophageal cancer	4.99e-05	0.000455	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—esophageal cancer	4.99e-05	0.000455	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	4.96e-05	0.000452	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—esophageal cancer	4.93e-05	0.000449	CcSEcCtD
Bortezomib—Confusional state—Methotrexate—esophageal cancer	4.83e-05	0.00044	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—esophageal cancer	4.79e-05	0.000436	CcSEcCtD
Bortezomib—Infection—Methotrexate—esophageal cancer	4.76e-05	0.000433	CcSEcCtD
Bortezomib—Hypersensitivity—Capecitabine—esophageal cancer	4.74e-05	0.000432	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—esophageal cancer	4.69e-05	0.000428	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—esophageal cancer	4.69e-05	0.000427	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—esophageal cancer	4.65e-05	0.000424	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—esophageal cancer	4.63e-05	0.000422	CcSEcCtD
Bortezomib—Asthenia—Capecitabine—esophageal cancer	4.61e-05	0.00042	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—esophageal cancer	4.56e-05	0.000416	CcSEcCtD
Bortezomib—Pruritus—Capecitabine—esophageal cancer	4.55e-05	0.000414	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—esophageal cancer	4.47e-05	0.000408	CcSEcCtD
Bortezomib—Diarrhoea—Capecitabine—esophageal cancer	4.4e-05	0.000401	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	4.36e-05	0.000397	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—esophageal cancer	4.33e-05	0.000394	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—esophageal cancer	4.3e-05	0.000392	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—esophageal cancer	4.27e-05	0.000389	CcSEcCtD
Bortezomib—Dizziness—Capecitabine—esophageal cancer	4.25e-05	0.000387	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—esophageal cancer	4.21e-05	0.000384	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—esophageal cancer	4.16e-05	0.000379	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—esophageal cancer	4.13e-05	0.000377	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—esophageal cancer	4.13e-05	0.000376	CcSEcCtD
Bortezomib—Pain—Methotrexate—esophageal cancer	4.09e-05	0.000373	CcSEcCtD
Bortezomib—Vomiting—Capecitabine—esophageal cancer	4.09e-05	0.000372	CcSEcCtD
Bortezomib—Rash—Capecitabine—esophageal cancer	4.05e-05	0.000369	CcSEcCtD
Bortezomib—Dermatitis—Capecitabine—esophageal cancer	4.05e-05	0.000369	CcSEcCtD
Bortezomib—Headache—Capecitabine—esophageal cancer	4.03e-05	0.000367	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—esophageal cancer	3.94e-05	0.000359	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—esophageal cancer	3.91e-05	0.000357	CcSEcCtD
Bortezomib—Nausea—Capecitabine—esophageal cancer	3.82e-05	0.000348	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—esophageal cancer	3.8e-05	0.000346	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—esophageal cancer	3.78e-05	0.000345	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—esophageal cancer	3.78e-05	0.000345	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—esophageal cancer	3.53e-05	0.000321	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—esophageal cancer	3.43e-05	0.000313	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—esophageal cancer	3.39e-05	0.000309	CcSEcCtD
Bortezomib—Diarrhoea—Methotrexate—esophageal cancer	3.28e-05	0.000298	CcSEcCtD
Bortezomib—Dizziness—Methotrexate—esophageal cancer	3.17e-05	0.000288	CcSEcCtD
Bortezomib—Vomiting—Methotrexate—esophageal cancer	3.04e-05	0.000277	CcSEcCtD
Bortezomib—Rash—Methotrexate—esophageal cancer	3.02e-05	0.000275	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—esophageal cancer	3.02e-05	0.000275	CcSEcCtD
Bortezomib—Headache—Methotrexate—esophageal cancer	3e-05	0.000273	CcSEcCtD
Bortezomib—Nausea—Methotrexate—esophageal cancer	2.84e-05	0.000259	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—CDKN1A—esophageal cancer	2.56e-06	1.45e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ABCB1—esophageal cancer	2.56e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.56e-06	1.45e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PSME2—esophageal cancer	2.54e-06	1.44e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PSME1—esophageal cancer	2.54e-06	1.44e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALDOB—esophageal cancer	2.54e-06	1.44e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GNG7—esophageal cancer	2.52e-06	1.43e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GSTT1—esophageal cancer	2.52e-06	1.43e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TYMP—esophageal cancer	2.5e-06	1.42e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—MYC—esophageal cancer	2.5e-06	1.41e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—MYC—esophageal cancer	2.5e-06	1.41e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—MYC—esophageal cancer	2.5e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP2A6—esophageal cancer	2.49e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.48e-06	1.41e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CA2—esophageal cancer	2.48e-06	1.4e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—MYC—esophageal cancer	2.46e-06	1.39e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GAPDH—esophageal cancer	2.46e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EP300—esophageal cancer	2.46e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—EGFR—esophageal cancer	2.46e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—EGFR—esophageal cancer	2.46e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—EGFR—esophageal cancer	2.46e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NOS3—esophageal cancer	2.45e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NOS3—esophageal cancer	2.45e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NOS3—esophageal cancer	2.45e-06	1.39e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EP300—esophageal cancer	2.45e-06	1.39e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GAPDH—esophageal cancer	2.44e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CRABP1—esophageal cancer	2.44e-06	1.38e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EP300—esophageal cancer	2.44e-06	1.38e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP26A1—esophageal cancer	2.43e-06	1.38e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—EGFR—esophageal cancer	2.42e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CRABP1—esophageal cancer	2.42e-06	1.37e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NOS3—esophageal cancer	2.42e-06	1.37e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALOX15—esophageal cancer	2.37e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALDH2—esophageal cancer	2.37e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ENO1—esophageal cancer	2.36e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS1—esophageal cancer	2.36e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PSME1—esophageal cancer	2.33e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PSME2—esophageal cancer	2.33e-06	1.32e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GNG7—esophageal cancer	2.32e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—MYC—esophageal cancer	2.32e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—MYC—esophageal cancer	2.32e-06	1.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—MYC—esophageal cancer	2.32e-06	1.31e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.3e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADH7—esophageal cancer	2.3e-06	1.3e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GNG7—esophageal cancer	2.3e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB2—esophageal cancer	2.29e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB2—esophageal cancer	2.29e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB2—esophageal cancer	2.29e-06	1.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—MYC—esophageal cancer	2.29e-06	1.29e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—EGFR—esophageal cancer	2.27e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—EGFR—esophageal cancer	2.27e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—EGFR—esophageal cancer	2.27e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTO1—esophageal cancer	2.26e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—TPI1—esophageal cancer	2.26e-06	1.28e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB2—esophageal cancer	2.26e-06	1.28e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GSTT1—esophageal cancer	2.25e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—EGFR—esophageal cancer	2.24e-06	1.27e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—EP300—esophageal cancer	2.23e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—EP300—esophageal cancer	2.23e-06	1.26e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—EP300—esophageal cancer	2.23e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP2A6—esophageal cancer	2.22e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.22e-06	1.26e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.22e-06	1.25e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—EP300—esophageal cancer	2.2e-06	1.24e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP1B1—esophageal cancer	2.19e-06	1.24e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PIK3CA—esophageal cancer	2.18e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALDH2—esophageal cancer	2.18e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALDOB—esophageal cancer	2.17e-06	1.23e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PIK3CA—esophageal cancer	2.17e-06	1.23e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALDH2—esophageal cancer	2.16e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PIK3CA—esophageal cancer	2.16e-06	1.22e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MYC—esophageal cancer	2.14e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MYC—esophageal cancer	2.13e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PIK3CA—esophageal cancer	2.13e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PIK3CA—esophageal cancer	2.13e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PIK3CA—esophageal cancer	2.13e-06	1.21e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MYC—esophageal cancer	2.12e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ENO1—esophageal cancer	2.11e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS1—esophageal cancer	2.11e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PIK3CA—esophageal cancer	2.1e-06	1.19e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EGFR—esophageal cancer	2.1e-06	1.19e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GAPDH—esophageal cancer	2.09e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EGFR—esophageal cancer	2.09e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PSME2—esophageal cancer	2.08e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PSME1—esophageal cancer	2.08e-06	1.18e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EGFR—esophageal cancer	2.08e-06	1.18e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GSTT1—esophageal cancer	2.07e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CRABP1—esophageal cancer	2.07e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP19A1—esophageal cancer	2.06e-06	1.17e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GSTT1—esophageal cancer	2.05e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP2A6—esophageal cancer	2.05e-06	1.16e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.03e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2A6—esophageal cancer	2.03e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCND1—esophageal cancer	2.03e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCND1—esophageal cancer	2.03e-06	1.15e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCND1—esophageal cancer	2.03e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.02e-06	1.14e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ADH1B—esophageal cancer	2.02e-06	1.14e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP1B1—esophageal cancer	2.01e-06	1.14e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCND1—esophageal cancer	2e-06	1.13e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PIK3CA—esophageal cancer	1.97e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PIK3CA—esophageal cancer	1.97e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PIK3CA—esophageal cancer	1.97e-06	1.11e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GNG7—esophageal cancer	1.97e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1A—esophageal cancer	1.96e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1A—esophageal cancer	1.96e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1A—esophageal cancer	1.96e-06	1.11e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—esophageal cancer	1.94e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.94e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ENO1—esophageal cancer	1.94e-06	1.1e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.94e-06	1.1e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1A—esophageal cancer	1.93e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TYMP—esophageal cancer	1.93e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.92e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ENO1—esophageal cancer	1.92e-06	1.09e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PSME1—esophageal cancer	1.91e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PSME2—esophageal cancer	1.91e-06	1.08e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PSME1—esophageal cancer	1.89e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PSME2—esophageal cancer	1.89e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP19A1—esophageal cancer	1.89e-06	1.07e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HMOX1—esophageal cancer	1.88e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.88e-06	1.06e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EP300—esophageal cancer	1.86e-06	1.06e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EP300—esophageal cancer	1.86e-06	1.06e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EP300—esophageal cancer	1.86e-06	1.06e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.84e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.84e-06	1.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EP300—esophageal cancer	1.84e-06	1.04e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.83e-06	1.04e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—esophageal cancer	1.82e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.81e-06	1.03e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—esophageal cancer	1.81e-06	1.03e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ABCB1—esophageal cancer	1.8e-06	1.02e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—esophageal cancer	1.8e-06	1.02e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.79e-06	1.01e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—esophageal cancer	1.76e-06	9.97e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.75e-06	9.93e-06	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—esophageal cancer	1.75e-06	9.92e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.75e-06	9.88e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—TPI1—esophageal cancer	1.75e-06	9.88e-06	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—esophageal cancer	1.74e-06	9.87e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.73e-06	9.81e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.73e-06	9.77e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HMOX1—esophageal cancer	1.72e-06	9.76e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CREBBP—esophageal cancer	1.71e-06	9.69e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.69e-06	9.57e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.69e-06	9.54e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.67e-06	9.47e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.65e-06	9.37e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ABCB1—esophageal cancer	1.65e-06	9.36e-06	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—esophageal cancer	1.65e-06	9.34e-06	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—esophageal cancer	1.65e-06	9.34e-06	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—esophageal cancer	1.65e-06	9.34e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.65e-06	9.34e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ENO1—esophageal cancer	1.64e-06	9.3e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.64e-06	9.3e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.63e-06	9.25e-06	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—esophageal cancer	1.63e-06	9.21e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MYC—esophageal cancer	1.62e-06	9.2e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MYC—esophageal cancer	1.62e-06	9.2e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MYC—esophageal cancer	1.62e-06	9.2e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSME1—esophageal cancer	1.62e-06	9.16e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PSME2—esophageal cancer	1.62e-06	9.16e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.61e-06	9.12e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MYC—esophageal cancer	1.6e-06	9.07e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.6e-06	9.04e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EGFR—esophageal cancer	1.59e-06	9e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EGFR—esophageal cancer	1.59e-06	9e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EGFR—esophageal cancer	1.59e-06	9e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EGFR—esophageal cancer	1.57e-06	8.87e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.55e-06	8.78e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.54e-06	8.71e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.54e-06	8.7e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—esophageal cancer	1.53e-06	8.67e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GNG7—esophageal cancer	1.52e-06	8.59e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.51e-06	8.54e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.48e-06	8.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.42e-06	8.05e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.41e-06	8.01e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.41e-06	8e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.4e-06	7.94e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTGS2—esophageal cancer	1.4e-06	7.93e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.4e-06	7.91e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—esophageal cancer	1.38e-06	7.81e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—esophageal cancer	1.38e-06	7.81e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—esophageal cancer	1.38e-06	7.81e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.38e-06	7.79e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.36e-06	7.72e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—esophageal cancer	1.36e-06	7.7e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.36e-06	7.69e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.35e-06	7.66e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.35e-06	7.62e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.34e-06	7.57e-06	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—esophageal cancer	1.33e-06	7.55e-06	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—esophageal cancer	1.33e-06	7.55e-06	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—esophageal cancer	1.33e-06	7.55e-06	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—esophageal cancer	1.32e-06	7.45e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.31e-06	7.44e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.27e-06	7.18e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ENO1—esophageal cancer	1.27e-06	7.18e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.25e-06	7.08e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSME2—esophageal cancer	1.25e-06	7.07e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PSME1—esophageal cancer	1.25e-06	7.07e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CREBBP—esophageal cancer	1.21e-06	6.83e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.2e-06	6.79e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.18e-06	6.66e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—EP300—esophageal cancer	1.17e-06	6.6e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.15e-06	6.51e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.12e-06	6.32e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CREBBP—esophageal cancer	1.11e-06	6.26e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—esophageal cancer	1.08e-06	6.11e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.08e-06	6.1e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.02e-06	5.76e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.01e-06	5.74e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—esophageal cancer	9.9e-07	5.6e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTGS2—esophageal cancer	9.87e-07	5.59e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CREBBP—esophageal cancer	9.87e-07	5.59e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HMOX1—esophageal cancer	9.25e-07	5.24e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CREBBP—esophageal cancer	9.08e-07	5.14e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTGS2—esophageal cancer	9.05e-07	5.12e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CREBBP—esophageal cancer	9e-07	5.09e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.88e-07	5.03e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—esophageal cancer	8.84e-07	5e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.7e-07	4.92e-06	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—esophageal cancer	8.62e-07	4.88e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—EP300—esophageal cancer	8.21e-07	4.65e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—esophageal cancer	8.13e-07	4.6e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTGS2—esophageal cancer	8.08e-07	4.57e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—esophageal cancer	8.06e-07	4.56e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CREBBP—esophageal cancer	7.69e-07	4.35e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—EP300—esophageal cancer	7.53e-07	4.26e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTGS2—esophageal cancer	7.43e-07	4.21e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTGS2—esophageal cancer	7.37e-07	4.17e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—esophageal cancer	6.88e-07	3.9e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—EP300—esophageal cancer	6.72e-07	3.8e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTGS2—esophageal cancer	6.3e-07	3.56e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—EP300—esophageal cancer	6.18e-07	3.5e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—EP300—esophageal cancer	6.13e-07	3.47e-06	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—esophageal cancer	6.08e-07	3.44e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.93e-07	3.36e-06	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—esophageal cancer	5.57e-07	3.15e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—esophageal cancer	5.31e-07	3.01e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—EP300—esophageal cancer	5.24e-07	2.96e-06	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—esophageal cancer	4.97e-07	2.81e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.86e-07	2.75e-06	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.57e-07	2.59e-06	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—esophageal cancer	4.53e-07	2.57e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—EP300—esophageal cancer	4.04e-07	2.29e-06	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.87e-07	2.19e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.99e-07	1.69e-06	CbGpPWpGaD
